Prior to joining LBG, Dr. Hantouche held a scientific position as a Study Director at an established contract research organization, ITR Laboratories Canada, Inc. During her 5-year tenure at ITR, Dr. Hantouche designed, executed, and managed more than 100 exploratory non-GLP and pivotal GLP-compliant toxicology studies ranging from single dose PK studies to repeat dose sub-acute, sub-chronic and chronic toxicity studies using various routes of administration (i.e., intraocular, oral, intraperitoneal, intravenous injection or infusion, dermal, and inhalation) in both small and large animals. As a Study Director, Dr. Hantouche served as the single point of study control from its initiation to its in-life conduct and through final reporting and interacted with regulatory bodies such the Standards Council of Canada (SCC) and the FDA during their on-site audits.
As a consultant at LBG for nonclinical product development and toxicology, Dr. Hantouche provides the indepth technical and scientific expertise necessary to advance drug development programs of a broad portfolio of sponsors, contract research organizations and academic institutions as well as federal, state, and local US government agencies. She brings in the subject matter expert (SME) knowledge and the creative customer focused mindset to provide advisory services along the pathway to approval of drugs, biologics, medical devices, and diagnostics.
Dr. Hantouche holds a PhD in Physiology from McGill University and an MBA from Concordia University.
